stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Operating cash flow
GeneDx Holdings Corp.'s operating cash flow for fiscal 2025 was $33.3M, compared with −$28.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$48.7M. Over the past ten years it has ranged from −$319.2M (fiscal 2022) to $33.3M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. GeneDx Holdings Corp. ranks 44th of 49 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $33.3M | — |
| FY2024 | −$28.5M | — |
| FY2023 | −$180.1M | — |
| FY2022 | −$319.2M | — |
| FY2021 | −$190.4M | — |
| FY2020 | −$93.1M | — |
| FY2019 | −$18.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$29.0M | — |
| Mar 2026 | −$32.4M | — |
| Dec 2025 | −$3.1M | — |
| Sep 2025 | $15.8M | 51.31% |
| 21 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| VCYT Veracyte, Inc. compare | $173.9M |
| CDNA CareDx, Inc. compare | $69.0M |
| CSTL Castle Biosciences, Inc. compare | $39.7M |
| NEO NeoGenomics, Inc. compare | $4.3M |
| FRNM Freenome, Inc compare | −$907.1K |
| ADPT Adaptive Biotechnologies Corporation compare | −$4.3M |
| WGS GeneDx Holdings Corp. | −$48.7M |
| PSNL Personalis, Inc. compare | −$97.6M |
| OPK OPKO Health, Inc. compare | −$125.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement